In conclusion, our research has shown that a cell-permeable fusion protein, sTRAIL:FeSOD, selectively sensitized K562 and HL-60 cancer cells to TRAIL-induced apoptosis but did not sensitize normal human hepatocytes (LO2 cells) or T cells. This evidence concerns the gene TNFSF10 and cancer.